Download PDF
Semin Liver Dis 2019; 39(03): 395-402
DOI: 10.1055/s-0039-1685517
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Treatment Options for Metastatic Gastrointestinal Stromal Tumors to the Liver: A Review

Heather A. Lillemoe
1   Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
,
Kristoffer W. Brudvik
2   Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Oslo, Norway
,
Jean-Nicolas Vauthey
1   Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
› Author Affiliations Funding Dr Heather Lillemoe is supported by the National Institutes of Health (T32 CA009599) and the MD Anderson Cancer Center support grant (P30 CA016672).
Further Information

Publication History

Publication Date:
17 May 2019 (online)

    Permissions and Reprints

Abstract

Up to half of patients with a gastrointestinal stromal tumor (GIST) will present with metastatic disease, most commonly involving the liver. Prior to the introduction of tyrosine kinase inhibitors, treatment options were limited for patients with metastatic GIST to the liver resulting in dismal survival rates. However, with the advent of effective systemic chemotherapy and continued advancements in both surgical and local adjunctive therapy options, significant improvements in survival have been achieved. In this review, the authors characterize the evolution of the treatment approach for metastatic GIST to the liver, including the roles of both surgical resection and adjunctive therapies in today's practice.

Keywords

stromal tumors - GIST - metastatic
 

  • References

  • 1 Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002; 3 (11) 655-664
    CrossrefPubMedGoogle Scholar
  • 2 Nilsson B, Bümming P, Meis-Kindblom JM. , et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden. Cancer 2005; 103 (04) 821-829
    CrossrefPubMedGoogle Scholar
  • 3 Turley RS, Peng PD, Reddy SK. , et al. Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Cancer 2012; 118 (14) 3571-3578
    CrossrefPubMedGoogle Scholar
  • 4 Quek R, George S. Gastrointestinal stromal tumor: a clinical overview. Hematol Oncol Clin North Am 2009; 23 (01) 69-78 , viii
    CrossrefPubMedGoogle Scholar
  • 5 Agaimy A, Wünsch PH. Lymph node metastasis in gastrointestinal stromal tumours (GIST) occurs preferentially in young patients < or = 40 years: an overview based on our case material and the literature. Langenbecks Arch Surg 2009; 394 (02) 375-381
    CrossrefPubMedGoogle Scholar
  • 6 Vassos N, Agaimy A, Hohenberger W, Croner RS. Extraabdominal lymph node metastasis in gastrointestinal stromal tumors (GIST). J Gastrointest Surg 2011; 15 (07) 1232-1236
    CrossrefPubMedGoogle Scholar
  • 7 Keung EZ, Fairweather M, Raut CP. The role of surgery in metastatic gastrointestinal stromal tumors. Curr Treat Options Oncol 2016; 17 (02) 8
    CrossrefPubMedGoogle Scholar
  • 8 Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152 (05) 1259-1269
    PubMedGoogle Scholar
  • 9 Hirota S, Isozaki K, Moriyama Y. , et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279 (5350): 577-580
    CrossrefPubMedGoogle Scholar
  • 10 Demetri GD, von Mehren M, Antonescu CR. , et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010; 8 (Suppl. 02) S1-S41 , quiz S42–S44
    PubMedGoogle Scholar
  • 11 Lamba G, Gupta R, Lee B, Ambrale S, Liu D. Current management and prognostic features for gastrointestinal stromal tumor (GIST). Exp Hematol Oncol 2012; 1 (01) 14
    CrossrefPubMedGoogle Scholar
  • 12 Tielen R, Verhoef C, van Coevorden F. , et al. Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?. World J Surg Oncol 2012; 10: 111
    CrossrefPubMedGoogle Scholar
  • 13 DeMatteo RP, Shah A, Fong Y, Jarnagin WR, Blumgart LH, Brennan MF. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 2001; 234 (04) 540-547 , discussion 547–548
    CrossrefPubMedGoogle Scholar
  • 14 Foster JH. Survival after liver resection for secondary tumors. Am J Surg 1978; 135 (03) 389-394
    CrossrefPubMedGoogle Scholar
  • 15 Jaques DP, Coit DG, Casper ES, Brennan MF. Hepatic metastases from soft-tissue sarcoma. Ann Surg 1995; 221 (04) 392-397
    CrossrefPubMedGoogle Scholar
  • 16 Nunobe S, Sano T, Shimada K, Sakamoto Y, Kosuge T. Surgery including liver resection for metastatic gastrointestinal stromal tumors or gastrointestinal leiomyosarcomas. Jpn J Clin Oncol 2005; 35 (06) 338-341
    CrossrefPubMedGoogle Scholar
  • 17 Pawlik TM, Vauthey JN, Abdalla EK, Pollock RE, Ellis LM, Curley SA. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg 2006; 141 (06) 537-543 , discussion 543–544
    CrossrefPubMedGoogle Scholar
  • 18 Husted TL, Neff G, Thomas MJ, Gross TG, Woodle ES, Buell JF. Liver transplantation for primary or metastatic sarcoma to the liver. Am J Transplant 2006; 6 (02) 392-397
    CrossrefPubMedGoogle Scholar
  • 19 Serralta AS, Sanjuan FR, Moya AH. , et al. Combined liver transplantation plus imatinib for unresectable metastases of gastrointestinal stromal tumours. Eur J Gastroenterol Hepatol 2004; 16 (11) 1237-1239
    CrossrefPubMedGoogle Scholar
  • 20 Joensuu H. Gastrointestinal stromal tumor (GIST). Ann Oncol 2006; 17 (Suppl. 10) x280-x286
    CrossrefPubMedGoogle Scholar
  • 21 Demetri GD, von Mehren M, Blanke CD. , et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347 (07) 472-480
    CrossrefPubMedGoogle Scholar
  • 22 Blanke CD, Rankin C, Demetri GD. , et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26 (04) 626-632
    CrossrefPubMedGoogle Scholar
  • 23 Casali PG, Abecassis N, Bauer S. , et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29 (Suppl. 04) iv68-iv78
    CrossrefPubMedGoogle Scholar
  • 24 Haller F, Detken S, Schulten H-J. , et al. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol 2007; 14 (02) 526-532
    CrossrefPubMedGoogle Scholar
  • 25 Chen LL, Trent JC, Wu EF. , et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004; 64 (17) 5913-5919
    CrossrefPubMedGoogle Scholar
  • 26 Heinrich MC, Corless CL, Demetri GD. , et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21 (23) 4342-4349
    CrossrefPubMedGoogle Scholar
  • 27 Antonescu CR, Besmer P, Guo T. , et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11 (11) 4182-4190
    CrossrefPubMedGoogle Scholar
  • 28 Zhu J, Yang Y, Zhou L, Jiang M, Hou M. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome. BMC Cancer 2010; 10: 199
    CrossrefPubMedGoogle Scholar
  • 29 von Mehren M, Randall RL, Benjamin RS. , et al. Soft tissue sarcoma, version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2018; 16 (05) 536-563
    CrossrefPubMedGoogle Scholar
  • 30 DeMatteo RP. Treatment of advanced gastrointestinal stromal tumor: a marriage of targeted therapy and surgery?. Ann Surg Oncol 2007; 14 (01) 1-2
    CrossrefPubMedGoogle Scholar
  • 31 Verweij J, Casali PG, Zalcberg J. , et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364 (9440): 1127-1134
    CrossrefPubMedGoogle Scholar
  • 32 Sym SJ, Ryu MH, Lee JL. , et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J Surg Oncol 2008; 98 (01) 27-33
    CrossrefPubMedGoogle Scholar
  • 33 DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007; 245 (03) 347-352
    CrossrefPubMedGoogle Scholar
  • 34 Bauer S, Rutkowski P, Hohenberger P. , et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib – analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol 2014; 40 (04) 412-419
    CrossrefPubMedGoogle Scholar
  • 35 Zalinski S, Palavecino M, Abdalla EK. Hepatic resection for gastrointestinal stromal tumor liver metastases. Hematol Oncol Clin North Am 2009; 23 (01) 115-127, ix ix.
    CrossrefPubMedGoogle Scholar
  • 36 Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006; 13 (10) 1271-1280
    CrossrefPubMedGoogle Scholar
  • 37 Shindoh J, Truty MJ, Aloia TA. , et al. Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. J Am Coll Surg 2013; 216 (02) 201-209
    CrossrefPubMedGoogle Scholar
  • 38 Mussi C, Ronellenfitsch U, Jakob J. , et al. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?. Ann Oncol 2010; 21 (02) 403-408
    CrossrefPubMedGoogle Scholar
  • 39 Machairas N, Prodromidou A, Molmenti E, Kostakis ID, Sotiropoulos GC. Management of liver metastases from gastrointestinal stromal tumors: where do we stand?. J Gastrointest Oncol 2017; 8 (06) 1100-1108
    CrossrefPubMedGoogle Scholar
  • 40 Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY. ; ESMO Guidelines Working Group. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl. 04) 64-67
    CrossrefPubMedGoogle Scholar
  • 41 ClinicalTrials.gov. SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST - Full Text View (n.d.). https://clinicaltrials.gov/ct2/show/NCT02924714 . Accessed 12 October, 2018.
    PubMedGoogle Scholar
  • 42 Hompland I, Bruland OS. Can imatinib be safely withdrawn in patients with surgically resected metastatic GIST?. Anticancer Res 2015; 35 (11) 5759-5765
    PubMedGoogle Scholar
  • 43 Seesing MF, Tielen R, van Hillegersberg R. , et al; Dutch Liver Surgery Working Group. Resection of liver metastases in patients with gastrointestinal stromal tumors in the imatinib era: A nationwide retrospective study. Eur J Surg Oncol 2016; 42 (09) 1407-1413
    CrossrefPubMedGoogle Scholar
  • 44 Cheung TT, Chok KS, Chan AC. , et al. Analysis of long-term survival after hepatectomy for isolated liver metastasis of gastrointestinal stromal tumour. ANZ J Surg 2014; 84 (11) 827-831
    CrossrefPubMedGoogle Scholar
  • 45 Xia L, Zhang MM, Ji L, Li X, Wu XT. Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors. Surg Today 2010; 40 (10) 936-942
    CrossrefPubMedGoogle Scholar
  • 46 Vassos N, Agaimy A, Hohenberger W, Croner RS. Management of liver metastases of gastrointestinal stromal tumors (GIST). Ann Hepatol 2015; 14 (04) 531-539
    CrossrefPubMedGoogle Scholar
  • 47 Chen H, Pruitt A, Nicol TL, Gorgulu S, Choti MA. Complete hepatic resection of metastases from leiomyosarcoma prolongs survival. J Gastrointest Surg 1998; 2 (02) 151-155
    CrossrefPubMedGoogle Scholar
  • 48 Shima Y, Horimi T, Ishikawa T. , et al. Aggressive surgery for liver metastases from gastrointestinal stromal tumors. J Hepatobiliary Pancreat Surg 2003; 10 (01) 77-80
    CrossrefPubMedGoogle Scholar
  • 49 Gomez D, Al-Mukthar A, Menon KV, Toogood GJ, Lodge JP, Prasad KR. Aggressive surgical resection for the management of hepatic metastases from gastrointestinal stromal tumours: a single centre experience. HPB (Oxford) 2007; 9 (01) 64-70
    CrossrefPubMedGoogle Scholar
  • 50 de la Fuente SG, Deneve JL, Parsons CM, Zager JS, Conley AP, Gonzalez RJ. A comparison between patients with gastrointestinal stromal tumours diagnosed with isolated liver metastases and liver metastases plus sarcomatosis. HPB (Oxford) 2013; 15 (09) 655-660
    CrossrefPubMedGoogle Scholar
  • 51 Brudvik KW, Patel SH, Roland CL. , et al. Survival after resection of gastrointestinal stromal tumor and sarcoma liver metastases in 146 patients. J Gastrointest Surg 2015; 19 (08) 1476-1483
    CrossrefPubMedGoogle Scholar
  • 52 Cananzi FC, Belgaumkar A, Lorenzi B, Mudan S. Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour. ANZ J Surg 2014; 84 (12) 937-942
    CrossrefPubMedGoogle Scholar
  • 53 Mise Y, Aloia TA, Brudvik KW, Schwarz L, Vauthey JN, Conrad C. Parenchymal-sparing hepatectomy in colorectal liver metastasis improves salvageability and survival. Ann Surg 2016; 263 (01) 146-152
    CrossrefPubMedGoogle Scholar
  • 54 Ye YJ, Gao ZD, Poston GJ, Wang S. Diagnosis and multi-disciplinary management of hepatic metastases from gastrointestinal stromal tumour (GIST). Eur J Surg Oncol 2009; 35 (08) 787-792
    CrossrefPubMedGoogle Scholar
  • 55 Yamanaka T, Takaki H, Nakatsuka A. , et al. Radiofrequency ablation for liver metastasis from gastrointestinal stromal tumor. J Vasc Interv Radiol 2013; 24 (03) 341-346
    CrossrefPubMedGoogle Scholar
  • 56 Yoon IS, Shin JH, Han K. , et al. Ultrasound-guided intraoperative radiofrequency ablation and surgical resection for liver metastasis from malignant gastrointestinal stromal tumors. Korean J Radiol 2018; 19 (01) 54-62
    CrossrefPubMedGoogle Scholar
  • 57 Jung JH, Won HJ, Shin YM, Kim PN. Safety and efficacy of radiofrequency ablation for hepatic metastases from gastrointestinal stromal tumor. J Vasc Interv Radiol 2015; 26 (12) 1797-1802
    CrossrefPubMedGoogle Scholar
  • 58 Jones RL, McCall J, Adam A. , et al. Radiofrequency ablation is a feasible therapeutic option in the multimodality management of sarcoma. Eur J Surg Oncol 2010; 36 (05) 477-482
    CrossrefPubMedGoogle Scholar
  • 59 Hakimé A, Le Cesne A, Deschamps F. , et al. A role for adjuvant RFA in managing hepatic metastases from gastrointestinal stromal tumors (GIST) after treatment with targeted systemic therapy using kinase inhibitors. Cardiovasc Intervent Radiol 2014; 37 (01) 132-139
    CrossrefPubMedGoogle Scholar
  • 60 van Tilborg AA, Scheffer HJ, de Jong MC. , et al. MWA versus RFA for perivascular and peribiliary CRLM: a retrospective patient- and lesion-based analysis of two historical cohorts. Cardiovasc Intervent Radiol 2016; 39 (10) 1438-1446
    CrossrefPubMedGoogle Scholar
  • 61 Lorentzen T, Skjoldbye BO, Nolsoe CP. Microwave ablation of liver metastases guided by contrast-enhanced ultrasound: experience with 125 metastases in 39 patients. Ultraschall Med 2011; 32 (05) 492-496
    Article in Thieme ConnectPubMedGoogle Scholar
  • 62 Scheffer HJ, Vroomen LG, Nielsen K. , et al. Colorectal liver metastatic disease: efficacy of irreversible electroporation--a single-arm phase II clinical trial (COLDFIRE-2 trial). BMC Cancer 2015; 15: 772
    CrossrefPubMedGoogle Scholar
  • 63 Brown KT, Do RK, Gonen M. , et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol 2016; 34 (17) 2046-2053
    CrossrefPubMedGoogle Scholar
  • 64 Cao G, Li J, Shen L, Zhu X. Transcatheter arterial chemoembolization for gastrointestinal stromal tumors with liver metastases. World J Gastroenterol 2012; 18 (42) 6134-6140
    CrossrefPubMedGoogle Scholar
  • 65 Rathmann N, Diehl SJ, Dinter D. , et al. Radioembolization in patients with progressive gastrointestinal stromal tumor liver metastases undergoing treatment with tyrosine kinase inhibitors. J Vasc Interv Radiol 2015; 26 (02) 231-238
    CrossrefPubMedGoogle Scholar
  • 66 Joensuu H, Eriksson M, Collan J, Balk MH, Leyvraz S, Montemurro M. Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: a prospective study. Radiother Oncol 2015; 116 (02) 233-238
    CrossrefPubMedGoogle Scholar